GO
Loading...

Medicine

More

  • So Much For The Summer Doldrums Friday, 1 Aug 2008 | 11:14 AM ET

    What a crazy week, right? Monday, Amgen had a huge upside revenue and earnings surprise. Tuesday, the Food and Drug Administration issued its new restrictions on the use of Amgen's anemia drugs in certain cancer patients. Later that same day, Elan and Wyeth released the big Alzheimer's drug test results.

  • Wyeth & Elan: Controlling The Countdown Tuesday, 29 Jul 2008 | 11:48 AM ET

    I'm at the International Conference on Alzheimer's Disease--aka ICAD--in Chicago where we're waiting for the highly anticipated detailed test results on the promising experimental drug from Wyeth and Elan.

  • Amgen's D-mab Delights Monday, 28 Jul 2008 | 10:38 AM ET
    AMGEN

    Amgen surprised the market late on a summer Friday by announcing positive test results from the big, crucial study of its experimental osteoporosis drug. The stock shot up after hours and continues to rally this morning.

  • The State of Statins & Stents Friday, 25 Jul 2008 | 11:14 AM ET
    Heart Stent

    Leerink Swann, which specializes in healthcare equities research, is out with a couple of noteworthy surveys--one on the collateral damage to Merck and Schering-Plough's Vytorin this week and the other on drug-coated stents from Abbott Labs, Boston Scientific, Johnson & Johnson and Medtronic.

  • Lilly, Pfizer & The Economies of ED Thursday, 24 Jul 2008 | 11:25 AM ET

    So, yesterday I posited a theory that the weak American economy might be hurting sales growth of erectile dysfunction drugs. I wondered whether men might be cutting their pills in half and/or not filling their expensive prescriptions if they're having to tighten their belts.

  • Is Pfizer's Viagra "Sagging" With The Economy? Wednesday, 23 Jul 2008 | 12:18 PM ET

    On the Pfizer earnings conference call this morning Chairman and CEO Jeff Kindler kicked things off by calling this a "time of great uncertainty in the world economy and capital markets and significant challenges in our industry."

  • Yesterday while covering the press conference about the new study on Merck and Schering-Plough's Vytorin I quoted the lead researcher, Dr. Terje Pedersen of Ulleval University Hospital in Oslo, Norway, who said--and this is a direct quote: "However, we had a disturbing finding when we looked at safety."

  • The buyout offer from Swiss drug giant Roche has shares of DNA trading at their highest level in about two-and-a-half years and according to CNBC stock-stat maven, Robert Hum, if they close up at least 8.88% it'll be their biggest one-day percentage gain since April 15, 2005.

  • Teva & Barr Get Super-Sized Friday, 18 Jul 2008 | 1:59 PM ET
    The Horsham, Pa., offices of Teva Pharmaceuticals North America are shown Monday, July 25, 2005.   In a deal that will create the world's largest generic drug company, Teva Pharmaceutical Industries Ltd. said Monday it is acquiring rival Ivax Corp. for about $7.4 billion (6.13 billion euros) in cash and stock. Ivax shares climbed 10 percent in morning trading.  (AP Photo/George Widman)

    arr's Chairman and CEO Bruce Downey told me Teva's CEO Schlomo Yanai made the first move. But it didn't happen in a long-distance phone call from Tel Aviv to New Jersey. They say they were at an industry conference in Palm Beach outside some burger joint when the subject came up.

  • Teva to Buy Barr for $7.5 Billion, Boosts Generic Lead Friday, 18 Jul 2008 | 10:41 AM ET
    The Horsham, Pa., offices of Teva Pharmaceuticals North America are shown Monday, July 25, 2005.   In a deal that will create the world's largest generic drug company, Teva Pharmaceutical Industries Ltd. said Monday it is acquiring rival Ivax Corp. for about $7.4 billion (6.13 billion euros) in cash and stock. Ivax shares climbed 10 percent in morning trading.  (AP Photo/George Widman)

    Teva Pharmaceutical Industries said on Friday it would buy rival generic drugmaker Barr Pharmaceuticals for $7.46  billion to expand its leadership in the U.S. market and fortify its presence in Europe.

  • Lilly's Sex Survey: Will It Have Desired Effect On Cialis? Wednesday, 16 Jul 2008 | 12:31 PM ET
    Lilly

    More than ten years after Pfizer brought Viagra to market and brought erectile dysfunction out of the closet a new survey says a lot of men are still too embarrassed to talk about impotence with their doctor.

  • Genentech Regenerates Avastin Tuesday, 15 Jul 2008 | 10:59 AM ET

    After a knee-jerk reaction to the downside after the closing bell yesterday to the surprising four-cent miss by Genentech, the shares are rallying big time in the early regular trading session.

  • Bobby Murcer Remembered Monday, 14 Jul 2008 | 10:43 AM ET
    Bobby Murcer as New York Yankees broadcaster

    Like so many people who knew Bobby Murcer or were fans of his, I was so sad to hear the news that he had passed away. I didn't know the man. And I only have vague childhood memories of then-Dodger Stadium announcer John Ramsey saying, "Bobby Murcer", when the "Yankee for Life" was playing for the Giants and Cubs at Chavez Ravine.

  • Elan In Double Trouble? Friday, 11 Jul 2008 | 11:32 AM ET
    Elan

    A few weeks ago I blogged about a couple analysts cautioning investors that shares of Irish drugmaker Elan would be volatile surrounding the Alzheimer's conference the end of this month.That has certainly proven to be the case, especially today as the second firm this week initiates coverage of the stock, but this time with a "Sell" rating.

  • Pfizer, Merck And Lilly Partner Up To Get "Enlightened" Thursday, 10 Jul 2008 | 10:30 AM ET

    Big pharma makes strange bedfellows. Pfizer, Merck and Eli Lilly this morning announced they've launched a joint venture of sorts called, "Enlight Biosciences". They're doing it with the help of the Boston-based VC firm PureTech Ventures.

  • Big Pharma Stocks: Real Rally Or One Day Wonder? Wednesday, 9 Jul 2008 | 11:19 AM ET
    Pharma Stocks

    One day does not a full-fledged sector rotation make, but yesterday the big pharma stocks put on a show and in the early going today the curtain hasn't fallen. Pfizer even broke above 18 bucks!

  • Cowen's "Elan" For Elan Tuesday, 8 Jul 2008 | 9:49 AM ET
    Elan

    At the risk of being ganged up on by the "Elanians" who will take umbrage with the fact that the biopharma team at Cowen and Company is not initiating coverage of the Irish drugmaker with a "screaming buy," I am blogging about the analysts' 50-page call on the stock today.

  • UBS And Its Guarded Outlook For Merck's Gardasil Monday, 7 Jul 2008 | 11:14 AM ET

    Shares of Merck, which have lost more than a third of their value so far this year, are under continued pressure this morning. They were at 60 bucks in early January. Today they're trading around $37. Big pharma analyst Rupesh Patel at UBS is downgrading the Dow component from Buy to Neutral because he thinks it's gonna be "range-bound near-term"...

  • Readers Get Short With Me--Over Amgen Thursday, 3 Jul 2008 | 11:08 AM ET

    Ahead of the long holiday weekend I thought this would be as good a time as any to once again go through the "Pharma's Market" mailbag. A couple of blog readers complained about my "short" story about Amgen.

  • Biopharma Analyst Musical Chairs Wednesday, 2 Jul 2008 | 11:16 AM ET

    In the world of nearly 400 publicly-traded biotechs, analyst coverage is especially important. Many of the firms are micro caps and when an analyst initiates coverage it can help put a baby biotech on investor and reporter radar screens.